Published in Nanomedicine (Lond) on February 13, 2012
Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics (2014) 1.29
Recent advances on smart TiO2 nanotube platforms for sustainable drug delivery applications. Int J Nanomedicine (2016) 0.78
Matrix metalloproteinases-2/9-sensitive peptide-conjugated polymer micelles for site-specific release of drugs and enhancing tumor accumulation: preparation and in vitro and in vivo evaluation. Int J Nanomedicine (2016) 0.75
Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials (2005) 2.77
The genetics of primary open-angle glaucoma: a review. Exp Eye Res (2008) 2.14
Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma. PLoS Genet (2012) 2.00
Analysis of LOXL1 polymorphisms in a United States population with pseudoexfoliation glaucoma. Mol Vis (2008) 1.87
TNXB mutations can cause vesicoureteral reflux. J Am Soc Nephrol (2013) 1.59
Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials (2005) 1.55
Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials (2007) 1.49
Major LOXL1 risk allele is reversed in exfoliation glaucoma in a black South African population. Mol Vis (2010) 1.45
Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials (2012) 1.39
Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials (2006) 1.32
Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials (2007) 1.29
Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel. Biomaterials (2003) 1.27
Formulation of Docetaxel by folic acid-conjugated d-α-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials (2011) 1.25
The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials (2006) 1.21
PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm Res (2003) 1.20
Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res (2013) 1.20
Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials (2009) 1.18
Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials (2008) 1.14
Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials (2013) 1.12
Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev (2012) 1.11
Paclitaxel drug delivery systems. Expert Opin Drug Deliv (2013) 1.09
Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials (2010) 1.08
No evidence of association of heterozygous NTF4 mutations in patients with primary open-angle glaucoma. Am J Hum Genet (2010) 1.08
Targeting and imaging cancer cells by folate-decorated, quantum dots (QDs)- loaded nanoparticles of biodegradable polymers. Biomaterials (2008) 1.07
The NEIGHBOR consortium primary open-angle glaucoma genome-wide association study: rationale, study design, and clinical variables. J Glaucoma (2013) 1.06
Genome-wide analysis of central corneal thickness in primary open-angle glaucoma cases in the NEIGHBOR and GLAUGEN consortia. Invest Ophthalmol Vis Sci (2012) 1.06
In vitro investigation on poly(lactide)-Tween 80 copolymer nanoparticles fabricated by dialysis method for chemotherapy. Biomacromolecules (2006) 1.04
In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials (2005) 1.02
Nanoparticles of poly(D,L-lactide)/methoxy poly(ethylene glycol)-poly(D,L-lactide) blends for controlled release of paclitaxel. J Biomed Mater Res A (2006) 1.01
Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials (2012) 1.01
A high-density genome-wide association screen of sporadic ALS in US veterans. PLoS One (2012) 1.00
Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer. J Control Release (2013) 1.00
In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm Res (2008) 1.00
Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials (2008) 1.00
Genome-wide association study and meta-analysis of intraocular pressure. Hum Genet (2013) 0.98
Spinocerebellar ataxias in mainland China: an updated genetic analysis among a large cohort of familial and sporadic cases. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2011) 0.98
The Genetics of Keratoconus: A Review. Reprod Syst Sex Disord (2012) 0.96
Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers. Biomaterials (2012) 0.96
Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma? J Surg Oncol (2014) 0.95
Superparamagnetic iron oxide--loaded poly(lactic acid)-D-alpha-tocopherol polyethylene glycol 1000 succinate copolymer nanoparticles as MRI contrast agent. Biomaterials (2010) 0.94
Hypothesis-independent pathway analysis implicates GABA and acetyl-CoA metabolism in primary open-angle glaucoma and normal-pressure glaucoma. Hum Genet (2014) 0.93
Modular TRAPP complexes regulate intracellular protein trafficking through multiple Ypt/Rab GTPases in Saccharomyces cerevisiae. Genetics (2012) 0.93
Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm (2011) 0.93
Effects of lipid chain unsaturation and headgroup type on molecular interactions between paclitaxel and phospholipid within model biomembrane. J Colloid Interface Sci (2005) 0.93
Nanoparticles of poly(lactide)-tocopheryl polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery. Biomaterials (2007) 0.93
Self-assembled nanoparticles of poly(lactide)--Vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm (2006) 0.92
Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. J Biomed Mater Res A (2010) 0.91
Effects of lipid chain length on molecular interactions between paclitaxel and phospholipid within model biomembranes. J Colloid Interface Sci (2004) 0.91
Multifunctional nanoparticles of biodegradable copolymer blend for cancer diagnosis and treatment. Nanomedicine (Lond) (2010) 0.91
Estrogen pathway polymorphisms in relation to primary open angle glaucoma: an analysis accounting for gender from the United States. Mol Vis (2013) 0.90
Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm (2010) 0.90
Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J Pharm Sci (2010) 0.90
A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials (2010) 0.90
Multimodal tumor imaging by iron oxides and quantum dots formulated in poly (lactic acid)-D-alpha-tocopheryl polyethylene glycol 1000 succinate nanoparticles. Biomaterials (2011) 0.89
Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy. Int J Pharm (2007) 0.89
Effects of material hydrophobicity on physical properties of polymeric microspheres formed by double emulsion process. J Control Release (2002) 0.89
Myocilin mutations in black South Africans with POAG. Mol Vis (2011) 0.88
Multifunctional silica nanoparticles for targeted delivery of hydrophobic imaging and therapeutic agents. Int J Pharm (2011) 0.88
Genome-wide linkage scan for primary open angle glaucoma: influences of ancestry and age at diagnosis. PLoS One (2011) 0.88
In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. Biomaterials (2007) 0.88
Vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicine. Nanomedicine (Lond) (2012) 0.87
Vitamin E (D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI. Biomaterials (2011) 0.87
Trs130 participates in autophagy through GTPases Ypt31/32 in Saccharomyces cerevisiae. Traffic (2012) 0.87
Folic acid-functionalized two-photon absorbing nanoparticles for targeted MCF-7 cancer cell imaging. Chem Commun (Camb) (2011) 0.86
Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. Int J Pharm (2010) 0.86
Pharmaceutical stability aspects of nanomedicines. Nanomedicine (Lond) (2009) 0.85
AQP1 and SLC4A10 as candidate genes for primary open-angle glaucoma. Mol Vis (2010) 0.85
A genome-wide association study of central corneal thickness in Latinos. Invest Ophthalmol Vis Sci (2013) 0.84
Association between chromosome 2p16.3 variants and glaucoma in populations of African descent. Proc Natl Acad Sci U S A (2010) 0.84
Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles. Biomaterials (2013) 0.83
d-alpha-Tocopheryl polyethylene glycol 1000 succinate (TPGS) modified poly(l-lactide) (PLLA) films for localized delivery of paclitaxel. Int J Pharm (2007) 0.83
CDKN2B-AS1 genotype-glaucoma feature correlations in primary open-angle glaucoma patients from the United States. Am J Ophthalmol (2012) 0.83
Block copolymer micelles for nanomedicine. Nanomedicine (Lond) (2012) 0.82
Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier. Nanomedicine (Lond) (2011) 0.82
Effects of cholesterol component on molecular interactions between paclitaxel and phospholipid within the lipid monolayer at the air-water interface. J Colloid Interface Sci (2006) 0.82
Low prevalence of myocilin mutations in an African American population with primary open-angle glaucoma. Mol Vis (2012) 0.82
Formulation, characterization, and in vitro evaluation of quantum dots loaded in poly(lactide)-vitamin E TPGS nanoparticles for cellular and molecular imaging. Biotechnol Bioeng (2008) 0.82
Polyethylenimine coating to produce serum-resistant baculoviral vectors for in vivo gene delivery. Biomaterials (2009) 0.82
Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. Biomaterials (2013) 0.81
EFFECT OF THE APOE ε4 ALLELE AND COMBAT EXPOSURE ON PTSD AMONG IRAQ/AFGHANISTAN-ERA VETERANS. Depress Anxiety (2015) 0.81
Novel powder formulations for controlled delivery of poorly soluble anticancer drug: application and investigation of TPGS and PEG in spray-dried particulate system. J Control Release (2005) 0.81
Theranostic liposomes for cancer diagnosis and treatment: current development and pre-clinical success. Expert Opin Drug Deliv (2012) 0.81
Nanomedicine: enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation. Curr Pharm Des (2010) 0.80
Herceptin functionalized polyhedral oligomeric silsesquioxane - conjugated oligomers - silica/iron oxide nanoparticles for tumor cell sorting and detection. Biomaterials (2011) 0.80
Antibody engineering promotes nanomedicine for cancer treatment. Nanomedicine (Lond) (2010) 0.80
Mitochondrial genetic background in Ghanaian patients with primary open-angle glaucoma. Mol Vis (2012) 0.80
siRNA-based nanomedicine. Nanomedicine (Lond) (2013) 0.80
Nanomedicine for multimodality treatment of cancer. Nanomedicine (Lond) (2012) 0.80
Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. Biomaterials (2011) 0.79
Prodrug micelle-based nanomedicine for cancer treatment. Nanomedicine (Lond) (2013) 0.79
Nanotheranostics: advanced nanomedicine for the integration of diagnosis and therapy. Nanomedicine (Lond) (2014) 0.79
Autophagy inhibition strategy for advanced nanomedicine. Nanomedicine (Lond) (2014) 0.79
Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. Expert Opin Drug Deliv (2013) 0.79
Nanoimmunotherapy: application of nanotechnology for sustained and targeted delivery of antigens to dendritic cells. Nanomedicine (Lond) (2012) 0.79
Vitamin E TPGS prodrug micelles for hydrophilic drug delivery with neuroprotective effects. Int J Pharm (2012) 0.79